Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 23.360
Filtrar
1.
Medicine (Baltimore) ; 99(2): e18568, 2020 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-31914035

RESUMEN

OBJECTIVE: Ginkgo biloba extract (GBE) is widely used as an adjunctive treatment for ischemic stroke. This meta-analysis aimed to evaluate the effectiveness and safety of GBE specifically for long-term users at the convalescence stage of ischemic stroke. METHODS: MEDLINE, Cochrane Central Register of Controlled Trials, Embase Database, WHO Clinical Trials Registration Platform, Chinese National Knowledge Infrastructure, Wanfang Database, and Chinese Scientific Journal Database were searched from inception to 20 September 2018. Risk ratio (RR) and mean difference (MD) with a 95% confidence interval (CI) were used as effect estimates using RevMan software (5.3; Review Manager [RevMan], Nordic Cochrane Centre, Copenhagen, Denmark). A meta-analysis was performed where data were available. A trial sequential analysis was used to control random errors for recurrence rate and the GRADE (grading of recommendations, assessment, development, and evaluations) approach was used to assess the quality of the body of evidence. The meta-analysis design was registered on PROSPERO (CRD42018110211, http://www.crd.york.ac.uk/PROSPERO). RESULTS: We identified 15 randomized clinical trials involving 1829 participants. The majority of the included trials were of high risk of bias in methodological quality. For acute ischemic stroke, adding GBE to conventional therapy led to higher Barthel index scores (MD: 5.72; 95% CI: 3.11-8.33) and lower neurological function deficit scores (MD: -1.39; 95% CI: -2.15 to -0.62). For patients in their convalescence (or sequelae) stage of ischemic stroke, GBE was superior in improving dependence (MD: 7.17; 95% CI: 5.96-8.38) and neurological function deficit scores (MD: -1.15; 95% CI: -1.76 to -0.53) compared with placebo or conventional therapy, but there was no difference in vascular events (RR: 0.70; 95% CI: 0.44-1.14), recurrence rate (RR: 0.57; 95% CI: 0.26-1.25; trial sequential analysis: conclusive) and mortality (RR: 1.07; 95% CI: 0.41-2.81). CONCLUSIONS: GBE appears to improve neurological function and dependence compared with conventional therapy for ischemic stroke at different stages and appears generally safe for clinical application. The lack of improvement in recurrence rate was confirmed by trial sequential analysis. Due to the generally weak evidence, further large, rigorous trials are warranted.


Asunto(s)
Isquemia Encefálica/tratamiento farmacológico , Extractos Vegetales/uso terapéutico , Accidente Cerebrovascular/tratamiento farmacológico , Quimioterapia Adyuvante , Humanos , Fitoterapia , Ensayos Clínicos Controlados Aleatorios como Asunto , Recurrencia
2.
Food Chem Toxicol ; 135: 110953, 2020 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-31707032

RESUMEN

Edible Sonchus oleraceus Linn is a medicinal plant with many bioactivities such as anti-diabetic activity and anti-inflammatory activity. However, the main bioactive components such as polyphenols in S. oleraceus Linn are poorly absorbed in gastrointestinal tract and rapidly metabolized. Thereby, a self-emulsifying delivery system containing S. oleraceus Linn extracts (SSEDDS) was introduced to evade these problems. Herein, the anti-inflammatory effect of SSEDDS on streptozotocin-induced diabetic rats was investigated. The plasma glucose level was increased and plasma insulin level was decreased in diabetic rats. The levels of NF-κB, TNF-α, and IL-6 in the liver were significantly improved in diabetic rats (p < 0.05). Conversely, daily fed diabetic rats with 100, 200 and 400 mg/kg/day of SSEDS and 1 mg/kg/day metformin for 4 weeks, significantly (p < 0.05) restored all the above mentioned parameters to near normal levels. The immuno-histochemical studies confirmed the anti-inflammatory effects of SSEDDS.


Asunto(s)
Antiinflamatorios/uso terapéutico , Diabetes Mellitus Experimental/tratamiento farmacológico , Emulsiones/uso terapéutico , Extractos Vegetales/uso terapéutico , Sonchus/química , Animales , Glucemia/metabolismo , Citocinas/metabolismo , Diabetes Mellitus Experimental/inducido químicamente , Hipoglucemiantes/uso terapéutico , Insulina/metabolismo , Hígado/efectos de los fármacos , Hígado/patología , Masculino , Ratas Sprague-Dawley , Estreptozocina
3.
Food Chem Toxicol ; 135: 111053, 2020 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-31857126

RESUMEN

Chronic pain management has several adverse effects and research looking for new and effective pain management drugs posing lower undesirable effects is necessary. Given the above, the pharmacological investigation of medicinal plants significantly contributes to the dissemination of plant-derived therapeutics. The aim of this study was to evaluate the antinociceptive activity of the Psidium brownianum Mart ex DC. leaf essential oil (PBEO) and the participation of the opioid pathway in this effect in mice. Swiss Mus musculus male mice were tested using acute nociception models (acetic acid induced abdominal contortions, formalin, capsaicin and hot plate tests). The possible myorelaxant action of the PBEO was tested using the rotarod test. The essential oil reduced animal nociception in chemical and heat models, with this action being devoid of a myorelaxant effect. Naloxone (2 mg/kg, intraperitoneally - i.p.) partially antagonized the PBEO activity, possibly acting via opioid receptors. The results obtained provide evidence that the traditional Psidium brownianum use may be effective for pain treatment.


Asunto(s)
Analgésicos/farmacología , Aceites Volátiles/farmacología , Extractos Vegetales/farmacología , Hojas de la Planta/química , Psidium/química , Animales , Modelos Animales de Enfermedad , Dosificación Letal Mediana , Masculino , Ratones , Nocicepción/efectos de los fármacos , Dolor/tratamiento farmacológico , Extractos Vegetales/uso terapéutico , Prueba de Desempeño de Rotación con Aceleración Constante
4.
Biosci Biotechnol Biochem ; 84(1): 187-197, 2020 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-31566092

RESUMEN

Walnut is a nutritious food material, but only a few studies have been conducted on the mechanisms of its functions and the technique for quality evaluation. Therefore, we analyzed the components in aqueous methanol extract of walnut, and characterized 30 components, including three new compounds, glansreginin C, ellagic acid 4-O-(3'-O-galloyl)-ß-D-xyloside, and platycaryanin A methyl ester. We analyzed the extracts of other nuts using HPLC and clarified that a characteristic peak corresponding to glansreginin A was mainly observed in walnut. These results suggested that glansreginin A might be an indicator component of the quality of walnut. We then examined whether glansreginin A has neuroprotective effect, using lipopolysaccharide (LPS)-induced inflammatory model mice. The results revealed that oral administration of glansreginin A prevented LPS-induced abnormal behavior and LPS-induced hyper-activation of microglia in the hippocampus. These results suggested that glansreginin A has the ability to exert neuroprotective effect via anti-inflammation in the brain.


Asunto(s)
Antiinflamatorios/farmacología , Juglans/química , Fármacos Neuroprotectores/farmacología , Valor Nutritivo , Extractos Vegetales/farmacología , Quinolinas/farmacología , Quinolonas/farmacología , Animales , Conducta Animal/efectos de los fármacos , Cromatografía Líquida de Alta Presión , Modelos Animales de Enfermedad , Ácido Elágico/farmacología , Hipocampo/patología , Inflamación/inducido químicamente , Inflamación/tratamiento farmacológico , Inflamación/prevención & control , Lipopolisacáridos/farmacología , Masculino , Metanol/química , Éteres Metílicos/farmacología , Ratones , Ratones Endogámicos ICR , Microglía/efectos de los fármacos , Extractos Vegetales/uso terapéutico , Quinolinas/uso terapéutico
5.
J Contemp Dent Pract ; 20(8): 920-927, 2019 Aug 01.
Artículo en Inglés | MEDLINE | ID: mdl-31797848

RESUMEN

AIM: The present study was conducted to compare the efficacy of all Punica granatum, Terminalia chebula, and Vitis vinifera on salivary Streptococcus mutans levels in children and also to evaluate their substantivity at an interval of 15 days that is at day 1, days 16, and 31. MATERIALS AND METHODS: This study was designed for a randomized clinical double-blinded study where 80 children of 8-15 years of age were living in a residential premise. Subjects were randomly divided into 4 groups of 20 each to whom mouthrinses were given. The criteria for assessing the efficacy was done by collecting the saliva sample for pH, buffering capacity, plaque index, and Streptococcus mutans microbiologic assay. These values were assessed at the baseline, days 16, and 31. Children were asked to discontinue mouthrinse from days 16 to 31. The supervisor was trained to administer the mouthrinses properly. RESULTS: The data were coded and analysis was done using the SPSS version 20. The level of significance was set at p < 0.05. The pH and buffering capacity showed that values were almost the same among all four groups at various time intervals which showed statistically nonsignificant results. Punica granatum showed a maximum reduction in S. mutans count followed by T. chebula and V. vinifera, although they were statistically nonsignificant. The Vitis vinifera group had successfully reduced more plaque score at day 16 (0.04) followed by T. chebula (0.09) and P. granatum (0.12). CONCLUSION: This in vivo study implied that V. vinifera had shown the lowest plaque reduction owing to its antioxidant and phytochemical properties. And P. granatum showed the maximum substantivity. CLINICAL SIGNIFICANCE: Mouthrinses helped in reducing plaque deposition, caries activity, and helped in oral hygiene maintenance. Hereby, we can conclude that nutraceutical mouthrinses are safe in children and produced superior results than the chemical mouthrinses.


Asunto(s)
Antisépticos Bucales , Extractos Vegetales , Streptococcus mutans , Terminalia , Adolescente , Niño , Humanos , Extractos Vegetales/uso terapéutico , Saliva , Semillas , Streptococcus mutans/efectos de los fármacos , Vitis
6.
Urologiia ; (5): 64-71, 2019 Dec.
Artículo en Ruso | MEDLINE | ID: mdl-31808635

RESUMEN

AIM: A comparative evaluation of the efficacy and safety of Canephron N and Cystone as monotherapy in women with acute uncomplicated cystitis and antibiotic allergy or intolerance was performed. MATERIALS AND METHODS: A prospective, randomized, controlled study of drug Canephron N as monotherapy for acute uncomplicated cystitis in 51 women with a history of antibiotic allergy or intolerance was carried out in 3 urological centers in Perm from 2016 to 2019. In the main group, patients received Canephron N for 30 days, while in comparison group, Cystone was prescribed. The Acute Cystitis Symptom Score (ACSS), microscopic study of urine sediment, urine culture and other methods were used. Results were evaluated 3, 6, 30 days and 1 year after the start of treatment. RESULTS: In the main group, monotherapy with Canephron N for 30 days resulted in a decrease in the total ACSS score from the baseline 12.9 to 0.3 points, while in Cyston group, changes of ACSS score were less pronounced, from baseline 12.8 to 1.4 points (p<0.01). Clinical cure rate in the main and comparison group was 88.5% and 68%, respectively. In another 3.8% and 1% of patients in the main and comparison group, an improvement was seen. The number of patients with leukocyturia in the Canephron N group decreased to 11.5% compared to 28% in Cyston group (p>0.05). Bacteriuria rate in the main group was 7.7%, which was less than in the comparison group (20%, p>0.05). Number of sick days in the main group was 4.9+/-0.4, compared to 7.4+/-0.6 days in Cyston group. In the Canephron N group, 1-year recurrence rate was only 7.7%, while in the Cyston group the recurrence was seen in 16% of patients. CONCLUSION: According to the results, Canephron N is an effective and safe drug as monotherapy for acute uncomplicated cystitis, and can be considered as drug of choice for the treatment of women with antibiotic allergy or intolerance.


Asunto(s)
Bacteriuria/tratamiento farmacológico , Cistitis/tratamiento farmacológico , Extractos Vegetales/uso terapéutico , Enfermedad Aguda , Adulto , Antibacterianos/administración & dosificación , Antibacterianos/efectos adversos , Bacteriuria/microbiología , Cistitis/microbiología , Femenino , Humanos , Hipersensibilidad , Estudios Prospectivos , Resultado del Tratamiento
7.
Medicine (Baltimore) ; 98(50): e18318, 2019 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-31852118

RESUMEN

BACKGROUND: Osteoarthritis (OA) is a major degenerative disease that affects the elderly. The global prevalence of OA is increasing annually. However, current treatments are unable to halt the progress of OA. At present, pharmacological treatments such as non-steroidal anti-inflammatory drugs (NSAIDs) and cyclooxygenase-2 (COX-2) inhibitors control the pain; however, there may be side effects to these medications. We hypothesized that Cortex Eucommiae (CE; Eucommia ulmoides Oliver) extract, which is used as a dietary supplement, may slow down or prevent OA. METHODS: This is a protocol for a 12-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of CE extract in subjects with mild OA. One-hundred subjects with mild OA will be recruited and randomly divided in a 1:1 ratio into 2 groups. One group will receive CE extract for 12 weeks and the other group will receive placebo for 12 weeks. Outcomes will be evaluated by using the visual analog scale (VAS), Korean-Western Ontario and McMaster Universities index (K-WOMAC), Korean-Short Form health survey-36 score (KSF-36), and laboratory test results. DISCUSSION: This clinical trial is expected to provide evidence of the efficacy and safety of CE extract as a treatment for mild OA. TRIAL REGISTRATION: Clinical Trials.gov NCT03744611, registered on November 12, 2018, at https://clinicaltrials.gov/ct2/show/NCT03744611.


Asunto(s)
Eucommiaceae , Articulaciones/diagnóstico por imagen , Osteoartritis/tratamiento farmacológico , Extractos Vegetales/uso terapéutico , Rango del Movimiento Articular/fisiología , Adulto , Anciano , Método Doble Ciego , Femenino , Estudios de Seguimiento , Humanos , Articulaciones/fisiopatología , Masculino , Persona de Mediana Edad , Osteoartritis/diagnóstico , Osteoartritis/fisiopatología , Radiografía , Índice de Severidad de la Enfermedad , Factores de Tiempo , Resultado del Tratamiento
8.
Medicine (Baltimore) ; 98(50): e18326, 2019 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-31852125

RESUMEN

BACKGROUND: Vascular dementia (VaD) is the second most common cause of dementia. The treatment of VaD still remains a challenge so far. Traditional Chinese Herbal medicine is a promising therapy due to their multiple components and targets. Shenmayizhi decoction (SMYZD), a Chinese Herbal prescription, has been reported its effective in alleviating cognitive dysfunction in clinical practice. However, strong clinical research of SMYZD in the treatment of VaD was lack. Therefore, we design this study to evaluate the adjuvant role of SMYZD in the treatment of VaD. METHODS: This is a multicenter, randomized, blind, controlled trial. A total of 196 eligible patients will be assigned to receive Ginkgo biloba extracts (GBEs) plus SMYZD granule or GBEs plus SMYZD mimetic granule in a 1:1 ratio. The duration of the trial will be 12 weeks, and a follow-up will be performed at the 24th week. The primary outcomes are the National Institute of Health stroke scale (NIHSS) and the Alzheimer Disease Assessment Scale-cognitive subscale (ADAS-cog). The secondary outcomes include the Mini-Mental State Examination (MMSE), the traditional Chinese Medicine (TCM) syndrome scale, Activities of Daily Living (ADL), concentrations of hypersensitive C-reactive protein (Hs-CRP), neuron-specific enolase (NSE) and homocysteine (HCY) in serum. Researchers will record any adverse events throughout the trial. DISCUSSION: This study will provide evidences to evaluate the efficacy and safety of SMYZD in combination with GBEs in treatment of VaD, as well as the adjuvant role of SMYZD in combination. TRIAL IS REGISTERED AT CHINESE CLINICAL TRIAL REGISTRY: ChiCTR1800017359.


Asunto(s)
Demencia Vascular/tratamiento farmacológico , Medicamentos Herbarios Chinos/uso terapéutico , Medicina China Tradicional/métodos , Actividades Cotidianas , Anciano , Quimioterapia Adyuvante/métodos , Femenino , Humanos , Masculino , Pruebas de Estado Mental y Demencia , Persona de Mediana Edad , Extractos Vegetales/uso terapéutico , Ensayos Clínicos Controlados Aleatorios como Asunto , Resultado del Tratamiento
9.
Zhongguo Zhong Yao Za Zhi ; 44(22): 4896-4904, 2019 Nov.
Artículo en Chino | MEDLINE | ID: mdl-31872598

RESUMEN

Previous studies of Dendrobium officinale on anti-hypertension effect always focused only on the blood pressure,while polysaccharides of D. officinale( DOP) have been traditionally considered as one of the main effective substances. This study aimed to evaluate the effect of ethanol extract from D. officinale( DOE) on blood pressure,Glu and lipid profile in metabolic hypertensive rats induced by comprehensive dietary factors,and elucidate the composition of effective fractions from DOE. A metabolic hypertension model of rat induced by high-sugar,high-fat diet and alcohol drinking was adopted to evaluate the effect of DOE on hypertension and other metabolic disorders. Blood pressure,Glu and lipid profile were detected to find the features and differences of DOE and DOP on metabolic hypertension. Furthermore,DOE was separated with three different common solvents according to the polarity. Along with blood pressure,Glu,UA and lipid profile,hemorheology,oxidative index and aortas structure changes were adopted to evaluate the comprehensive effects of the most effective fractions on metabolic hypertension. Finally,HPLC-DAD-MS was adopted to identify the components of the most effective fraction. The SBP and Glu of models were decreased significantly after administration of DOE and DOP for 6 weeks,while TG in DOE groups also reduced dramatically. The DOE was separated with ether,n-butanol respectively and named NAF,NBF and NCF. SBP,TG,Glu,UA of model rats were decreased significantly after 4 weeks administration with NBF. The level of MDA in serum was down-regulated,while GSH-Px and T-AOC were up-regulated obviously after 12 weeks.And the blood viscosity also obviously decreased,with less collagen deposition of aortas by Masson's trichrome staining. NBF was mainly composed of phenols and flavone C-glycosides,whose aglycone was apigenin,and monosaccharide was connected to C-6 and C-8. Ethanol extract from D.officinale has an positive effect in alleviating hypertension and metabolic disorders in metabolic hypertension. Medium polarity fraction was the effective fraction of alcohol extraction from D. officinale,and mainly composed of phenols and flavone C-glycosides.


Asunto(s)
Dendrobium , Hipertensión/tratamiento farmacológico , Extractos Vegetales/uso terapéutico , Animales , Presión Sanguínea , Etanol , Extractos Vegetales/farmacología , Ratas
10.
Medicine (Baltimore) ; 98(47): e18060, 2019 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-31764835

RESUMEN

OBJECTIVE: A retrospective chart review was conducted to explore the effect of Gambisan, a granular extract of novel herbal medicine, for short-term (≤16 weeks) weight loss in adults who are overweight and those with obesity. METHODS: Outpatients of Kyung Hee University Korean Medicine Hospital (Seoul, Korea) who took Gambisan and underwent bioelectric impedance analysis were selected (Jan 2011 to Dec 2015); their electronic medical records and clinical charts were retrospectively reviewed. The effectiveness of Gambisan was primarily evaluated by comparing body weight (BW) at baseline and endpoint, using paired t tests; the safety of Gambisan was evaluated on the basis of adverse events (AEs) experienced by patients. RESULTS: Two hundred five patients were included in this study. The study population exhibited a significant reduction in BW (73.69 ±â€Š14.49 kg to 69.01 ±â€Š13.20 kg, P < .001) as well as percentage body fat (37.38 ±â€Š5.38% to 34.50 ±â€Š5.83%, P < .001). Moreover, 111 (54.1%) patients achieved modest weight loss (≥5%), while 35 (17.1%) achieved ≥10% weight loss. Furthermore, Gambisan induced significant reduction of BW in all subgroups (body mass index, sex, prescribed duration, and dosage). Among 139 patients with available data, 79 (56.8%) reported loss-of-appetite. In addition, 120 (mostly mild) AEs were reported in 69 (49.6%) patients, and the most frequent AEs were nausea, palpitation, and insomnia. DISCUSSION: Despite limitations in interpreting the results of this retrospective medical record review, Gambisan induced statistically and clinically meaningful weight loss with a tolerable level of AEs. Based on the findings of this review, further well-designed clinical trials are warranted.


Asunto(s)
Sobrepeso/tratamiento farmacológico , Fitoterapia , Extractos Vegetales/farmacología , Extractos Vegetales/uso terapéutico , Pérdida de Peso/efectos de los fármacos , Femenino , Humanos , Masculino , Persona de Mediana Edad , Obesidad/tratamiento farmacológico , Estudios Retrospectivos , Factores de Tiempo
11.
Environ Health Prev Med ; 24(1): 62, 2019 Nov 23.
Artículo en Inglés | MEDLINE | ID: mdl-31759394

RESUMEN

BACKGROUND: Mercury has been documented as an industrial risk that posed a serious danger to human health. Mercury exposure results in oxidative stress that may lead to the pathogenesis of male reproductive dysfunction. The present study investigated the ameliorating potential of Chenopodium album L. and vitamin C against mercuric chloride-induced oxidative deterioration of reproductive functions in adult male rats. METHODS: Group 1 (control) received saline. Group 2 received Mercury (0.15 mg/kg b.w, i.p) dissolved in distilled water. Groups 3 and 4 were given oral gavage of vitamin C (200 mg/kg b.w) and the ethanolic extract of C. album (200 mg/kg b.w) respectively, along with Mercury (0.15 mg/kg b.w, i.p). Group 5 was treated only with C. album (200 mg/kg b.w). After 30 days of the treatment, the rats were dissected and their testicular tissue and the cauda epididymis were used for biochemical analysis while blood plasma was used for protein determination. RESULTS: The applied dose-treatment of Mercury-induced oxidative stress in the testis and cauda epididymis tissues of the rats was apparent by a noteworthy decrease in total protein, CAT, SOD, POD, and GST values while there was increase in ROS and TBARS levels. Furthermore, Mercury decreases daily sperm production and enhanced sperm DNA damage as noticeable by an increase in the head and tail length of comets and decrease in intact DNA. There was no significant effect on the body weight and the weight of the reproductive tissues. Treatment with C. album significantly ameliorated the total protein, ROS, and TBARS content. Similarly, the level of CAT, SOD, POD, and GST was significantly improved and the daily sperm production was significantly increased. Furthermore, C. album administration significantly protected Mercury-induced sperm DNA damage. The results of the extract treatment group were compared with those of vitamin C in detoxifying the oxidative stress and restoring the sperm parameters. CONCLUSION: C. album showed protection against Mercury-induced oxidative stress by ameliorating antioxidant enzyme activity, daily sperm production, and DNA damage in rat testes. This suggests that C. album could be beneficial against toxicity induced by an environmental toxicant.


Asunto(s)
Ácido Ascórbico/uso terapéutico , Chenopodium album/química , Cloruro de Mercurio/toxicidad , Estrés Oxidativo/efectos de los fármacos , Extractos Vegetales/uso terapéutico , Testículo/efectos de los fármacos , Animales , Antioxidantes/metabolismo , Ácido Ascórbico/administración & dosificación , Daño del ADN/efectos de los fármacos , Quimioterapia Combinada , Masculino , Extractos Vegetales/administración & dosificación , Extractos Vegetales/química , Ratas Sprague-Dawley , Especies Reactivas de Oxígeno/metabolismo , Espermatogénesis/efectos de los fármacos , Testículo/metabolismo , Testículo/fisiología , Resultado del Tratamiento
12.
BMC Complement Altern Med ; 19(1): 327, 2019 Nov 21.
Artículo en Inglés | MEDLINE | ID: mdl-31752836

RESUMEN

BACKGROUND: The control of biofilm adherence on tooth surface has always been the keystone of periodontal therapeutic systems. However, prevalence of gingivitis suggest inadequacy of self-performed oral hygiene measures and need for adjunctive aid for mechanical plaque control. Oral rinses containing chlorhexidine, has been widely used however, with certain limitations. Herbal products have been used widely reflecting its action as alternative and complementary remedy. Hence, the purpose of the present study was to evaluate the antimicrobial and antioxidant efficacy of a Guava leaf extract based mouthrinse in patients with chronic generalized gingivitis as an adjunct to oral prophylaxis. METHODS: Sixty subjects (n = 20) in compliance with the inclusion criteria were randomly assigned to one of the 3 study groups i.e. Group A- 0.15%Guava mouth rinse, Group B- 0.2% Chlorhexidine (CHX) mouth rinse, Group C- Distilled water (placebo). All the participants received professional oral prophylaxis and were dispensed with experimental mouth rinses and instructed to use for period of 30 days. Clinical parameters such as gingival index, plaque index along with microbial colony forming units using plaque samples and antioxidant levels in saliva were estimated at baseline, 30 and 90 days' time intervals. RESULTS: All 3 groups showed gradual reduction in GI, PI and microbial counts. Considering the mean scores of recorded parameters at the scheduled time intervals, notable changes were observed between chlorhexidine and guava mouth rinse compared to placebo group. Although there was improvement in the antioxidant status in all study participants, yet there was no statistically significant difference observed. CONCLUSION: Guava mouth rinse can be used as an empirical adjunct to professional oral prophylaxis owing to its multifactorial properties and favourable acceptance. However, long term studies need to be conducted to validate its use for an extended period of time. TRIAL REGISTRATION: The clinical trial has been prospectively registered on 17th February 2017 by the Clinical Trials Registry-India (CTRI/2017/02/007898).


Asunto(s)
Antisépticos Bucales , Higiene Bucal/métodos , Extractos Vegetales , Psidium , Adolescente , Adulto , Antiinfecciosos Locales/farmacología , Antiinfecciosos Locales/uso terapéutico , Antioxidantes/análisis , Clorhexidina/farmacología , Clorhexidina/uso terapéutico , Recuento de Colonia Microbiana , Placa Dental/microbiología , Femenino , Gingivitis/tratamiento farmacológico , Gingivitis/microbiología , Humanos , Masculino , Antisépticos Bucales/farmacología , Antisépticos Bucales/uso terapéutico , Extractos Vegetales/farmacología , Extractos Vegetales/uso terapéutico , Hojas de la Planta/química , Saliva/química , Saliva/efectos de los fármacos , Saliva/microbiología , Adulto Joven
13.
BMC Complement Altern Med ; 19(1): 290, 2019 Oct 30.
Artículo en Inglés | MEDLINE | ID: mdl-31666058

RESUMEN

BACKGROUND: Nigella sativa or commonly known as black seed or black cumin is one of the most ubiquitous complementary medicine. Epithelial to mesenchymal transition (EMT) of type 2 is defined by the balance between wound healing and tissue fibrosis, which is dependent to the state of inflammation. This systematic review is conducted to provide an overview regarding the reported effect of Nigella sativa and its bioactive compound on the type 2 EMT. METHODS: A search was done in EBSCOHOST, OVID and SCOPUS database to obtain potentially relevant articles that were published between 1823 and August 2019. This review includes studies that focus on the effect of Nigella sativa and its bioactive compound on the events related to type 2 EMT. RESULTS: A total of 1393 research articles were found to be potentially related to the effect of Nigella sativa and its bioactive compound, thymoquinone on Type 2 EMT. After screening was done, 22 research articles met inclusion criteria and were included in this review. Majority of the studies, reported better wound healing rate or significant prevention of tissue inflammation and organ fibrosis following Nigella sativa or thymoquinone treatments. In terms of wound healing, studies included reported progression of EMT related pathological changes after treatment with Nigella sativa or thymoquinone. Alternatively, in terms of fibrosis and inflammation, studies included reported reversal of pathological changes related to EMT after treatment with Nigella sativa or thymoquinone. CONCLUSION: Through this review, Nigella sativa and thymoquinone have been associated with events in Type 2 EMT. They have been shown to promote wound healing, attenuate tissue inflammation, and prevent organ fibrosis via regulation of the EMT process.


Asunto(s)
Transición Epitelial-Mesenquimal/efectos de los fármacos , Nigella sativa/química , Extractos Vegetales/química , Extractos Vegetales/uso terapéutico , Heridas y Traumatismos/tratamiento farmacológico , Animales , Benzoquinonas/análisis , Benzoquinonas/uso terapéutico , Humanos , Fitoterapia , Resultado del Tratamiento , Heridas y Traumatismos/fisiopatología
14.
Pain Res Manag ; 2019: 6320163, 2019.
Artículo en Inglés | MEDLINE | ID: mdl-31687058

RESUMEN

None of the clinical trials on migraine conducted thus far have focused on the possibility to modulate the phenomenon of aura. Furthermore, whether proper management of aura results in a better control of the headache phase has been poorly investigated. In the setting of a single-center, pilot, clinical trial, we aimed at comparing the effects of Aurastop (a combination of tanacetum parthenium (150 mg extracted at 0.8% = 1.2 mg di of active parthenolide), griffonia simplicifoila (20 mg of 5-hydroxy tryptophan), and magnesium (185 mg of magnesium pidolatum)) with those of magnesium alone (2.25 grams/tablet, corresponding to 184 mg of Mg++) in the treatment of acute attacks of migraine with aura. Between June 2017 and June 2018, 50 consecutive patients (27/23 male/female; mean age, 31 [18-57] years) with at least 3 episodes of aura per year were included (t 0). Participants were instructed to keep track of the following 4 episodes of migraine with aura (t 1) and invited to assume (1) a tablet of Aurastop at the beginning of the following 2 episodes of aura and (2) a magnesium tablet alone at the occurrence of the third and fourth aura attacks. Forty-eight patients (96.0%) had >50% reduction in aura duration when treated with Aurastop vs. 7 patients (14.0%) when treated with magnesium alone (p < 0.001); 48 patients (96.0%) had >50% reduction of aura-related disability when receiving Aurastop vs. 5 patients (10.0%) when treated with magnesium alone (p < 0.001); however, patients receiving Aurastop did not need to take pain killers in 35% of aura attacks vs. 3% when assuming magnesium (p < 0.001). These results support the hypothesis that Aurastop might be effective in interfering with the phenomenon of aura and provide evidence that the clinical benefit attributable to this combination of molecules might be greater than that obtained with single compounds of proven effect on the biology of migraine.


Asunto(s)
Magnesio/uso terapéutico , Migraña con Aura/tratamiento farmacológico , Extractos Vegetales/uso terapéutico , Triptófano/uso terapéutico , Adolescente , Adulto , Femenino , Humanos , Masculino , Persona de Mediana Edad , Proyectos Piloto , Tanacetum parthenium , Adulto Joven
15.
Medicine (Baltimore) ; 98(46): e17925, 2019 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-31725644

RESUMEN

BACKGROUND: Erectile dysfunction (ED) affects many adult men worldwide. Many studies on the brain of psychogenic ED have shown significant cerebral functional changes and reduced volume of gray matter and white matter microstructural alterations in widespread brain regions. Chaihu-Shugan-San (CHSGS) capsule has been used to treat ED from the 20th century in China. However, clinical research of CHSGS capsule in the treatment of ED was lack. We design this study to evaluate the efficacy and safety of CHSGS capsule in the treatment of patients suffering from psychogenic ED. Furthermore, we also aim to provide a new evidence as well as an innovation of the clinical treatment in psychogenic ED. METHODS: This study is designed as a multi-center, 3-arms, randomized trial. From the perspective of psychogenic ED, we will divide patients into 3 groups, which are placebo group, tadalafil group and CHSGS group. One hundred thirty-five patients will be randomly allocated to receive placebo, CHSGS capsule or tadalafil oral pharmacotherapy. After the period of 4-week treatment, the outcome of primary assessment changes in the brain MRI, IIEF-5, EHS, and QEQ total scores from baseline. Secondary assessments include the SEAR, HAMA-14, HAMD-17 scores, response rate of the patients and their partners. DISCUSSION: We designed this study based on previous research about psychogenic erectile dysfunction (ED). This study will provide objective evidences to evaluate the effects of CHSGS capsule as an adjuvant treatment for psychogenic ED. TRIAL REGISTRATION NUMBER: chictr.org.cn, ChiCTR-IOR-1800018301.


Asunto(s)
Disfunción Eréctil/terapia , Extractos Vegetales/uso terapéutico , Tadalafilo/uso terapéutico , Vasodilatadores/uso terapéutico , Adulto , Método Doble Ciego , Disfunción Eréctil/tratamiento farmacológico , Humanos , Masculino , Extractos Vegetales/administración & dosificación , Extractos Vegetales/efectos adversos , Tadalafilo/administración & dosificación , Tadalafilo/efectos adversos , Vasodilatadores/administración & dosificación , Vasodilatadores/efectos adversos , Adulto Joven
16.
J Biochem Mol Toxicol ; 33(12): e22410, 2019 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-31617649

RESUMEN

Multiple sclerosis (MS) is an autoimmune disease in which the immune system attacks the nerve cells, resulting in neurological disorders. Oxidative stress, free radicals, and neuritis have important roles in MS pathogenesis. Here, we aim to evaluate the effect of crocin on inflammatory markers, oxidative damage, and deoxyribonucleic acid (DNA) damage in the blood of patients with MS. A total of 40 patients were divided into two groups, drug and placebo-treated groups, using random assignment. Participants of the intervention and control groups received two crocin capsules or placebo per day for 28 days, respectively. Findings revealed a significant decrease in the level of important pathogenic factors in MS, including lipid peroxidation, DNA damage, tumor necrosis factor-alpha, and interleukin 17 as well as a significant increase in the total antioxidant capacity in the serum of patients treated with crocin compared with the placebo group. Our results suggest the beneficial and therapeutic effects of crocin in MS.


Asunto(s)
Antioxidantes/uso terapéutico , Carotenoides/uso terapéutico , Daño del ADN/efectos de los fármacos , Inflamación/tratamiento farmacológico , Esclerosis Múltiple/tratamiento farmacológico , Estrés Oxidativo/efectos de los fármacos , Extractos Vegetales/uso terapéutico , Adulto , Antioxidantes/administración & dosificación , Biomarcadores/sangre , Carotenoides/administración & dosificación , Crocus/química , Método Doble Ciego , Femenino , Humanos , Interleucina-17/sangre , Peroxidación de Lípido/efectos de los fármacos , Masculino , Esclerosis Múltiple/sangre , Extractos Vegetales/administración & dosificación , Factor de Necrosis Tumoral alfa/sangre , Adulto Joven
17.
Medicine (Baltimore) ; 98(43): e17573, 2019 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-31651859

RESUMEN

RATIONALE: Patients with end-stage kidney disease (ESKD) receiving maintenance dialysis experience an overall burden of physical and emotional symptoms. However, there were limited alternative treatments to dialysis. PATIENT CONCERNS: A 79-year-old woman with chronic kidney disease stage 5 (CKD5) and gout had refused to be on dialysis. She also had hypoglycemia, hypertension, and heart disease. DIAGNOSES: The patient had received the ultrasonography, the renal biopsy and biochemical examinations, confirming the diagnosis of renal impairment, primary hypertension, and chronic nephritic syndrome with unspecified morphologic changes. INTERVENTIONS: She was administered with 20 mL Eefooton (a liquid formula of herbal extracts: Astragalus membranaceus 3 g, Codonopsis pilosula 3 g, Ligustrum lucidum 3 g, Panax quinquefolius 1.3 g, and Rhodiola sacra 1.3 g) orally twice a day for 6 months in addition to her regular medications. OUTCOMES: The patient was followed up for 3 months after the completion of the Eefooton adjuvant treatment. The patient's renal function was improved, and CKD progression was alleviated. After Eefooton treatment, the sizes of both kidneys in the patient increased by 8% while blood urea nitrogen (BUN) and serum creatinine concentrations were decreased. In addition, further reduction in BUN concentration was observed 2 months posttreatment. LESSONS: This case demonstrated that Eefooton has potential therapeutic significance in patients with CKD5 who chose conservative treatment over dialysis.


Asunto(s)
Tratamiento Conservador/métodos , Fitoterapia/métodos , Extractos Vegetales/uso terapéutico , Insuficiencia Renal Crónica/tratamiento farmacológico , Anciano , Progresión de la Enfermedad , Femenino , Humanos , Insuficiencia Renal Crónica/complicaciones , Resultado del Tratamiento
18.
Medicine (Baltimore) ; 98(43): e17655, 2019 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-31651889

RESUMEN

BACKGROUND: Though several neuroprotective agents have been evaluated as potential treatments for acute ischemic stroke, none have demonstrated a definitive treatment efficacy, which remains elusive. HT047 is an herbal extract of Scutellaria baicalensis and Pueraria lobata, both of which have been widely used to treat ischemic stroke in traditional Korean medicine. The aims of this trial are to investigate whether HT047 can improve neurologic status, particularly motor function, in acute ischemic stroke patients, and to determine the safety of HT047. METHODS: A multicenter, double-blind, randomized, placebo-controlled, 3-arm parallel group, phase II trial will be conducted in patients who have had an acute ischemic stroke within the past 14 days. The participating patients must have a Fugl-Meyer assessment (FMA) motor score ≤55, with arm or leg weakness, and Korean version of the National Institutes of Health Stroke scale (K-NIHSS) score of ≥4 and ≤15. Seventy-eight participants will be randomized in a 1:1:1 ratio and given high-dose HT047 (750 mg 3 times a day), low-dose HT047 (500 mg 3 times a day), or a placebo for 12 weeks. The primary endpoint is the change in FMA motor score between baseline and week 12. Secondary endpoints are as follows: the change in FMA motor score at weeks 4 and 8 from baseline; the change in FMA motor score at weeks 4, 8, and 12 from baseline according to the timing of treatment initiation (either within 1 week, or 1-2 weeks), or according to the presence of prognostic risk factors (hypertension, diabetes, dyslipidemia, etc); the change in K-NIHSS and Korean versions of the modified Rankin scale (K-mRS) and the modified Barthel index at weeks 4 and 12 from baseline; and the proportion of subjects at week 12 with a K-NIHSS score of 0 to 2, or with K-mRS scores of 0, ≤1, and ≤2. DISCUSSION: This study is a 1st-in-human trial of HT047 to explore the efficacy and safety in acute ischemic stroke patients. The results will provide the appropriate dosage and evidence of therapeutic benefit of HT047 for stroke recovery. TRIAL REGISTRATION: ClinicalTrials.gov (NCT02828540) Registered July 11, 2016.


Asunto(s)
Isquemia Encefálica/tratamiento farmacológico , Fitoterapia/métodos , Extractos Vegetales/uso terapéutico , Pueraria/química , Scutellaria/química , Accidente Cerebrovascular/tratamiento farmacológico , Método Doble Ciego , Humanos , República de Corea , Proyectos de Investigación
19.
Int Braz J Urol ; 45(5): 1043-1054, 2019.
Artículo en Inglés | MEDLINE | ID: mdl-31626524

RESUMEN

OBJECTIVE: Anacyclus Pyrethrum (AP) and Tribulus Terrestris (TT) have been reported as male infertility treatment in several studies; however, in Iranian traditional medicine these two plants are prescribed simultaneously. In this study, we aimed to determine the effects of AP and TT extracts both separately and simultaneously on the male Wistar rat fertility parameters. MATERIALS AND METHODS: 32 male Wistar rats were divided into 4 groups: Control, TT, AP, and AT treated groups. Treatment continued for 25 days and rats were weighed daily. Their testes were dissected for histological studies. Sperm analysis including sperm count, viability and motility were performed. Serum was obtained to evaluate testosterone, LH and FSH levels. Histological studies were conducted to study Leydig, and Sertoli cells, spermatogonia and spermatid cell numbers, and to measure seminiferous diameter and epithelium thickness. RESULTS: Sperm count increased in all the treatment groups. Sperm viability and motility in AT and AP groups were elevated. TT and AT groups showed signifi cantly increased testosterone level compared to control group (P=004, P=0.000, respectively) and TT, AP and AT treatment groups showed increased LH level (P=0.002, P=0.03 and P=0.000, respectively) compared to control, while only AT group showed increased FSH (p=0.006) compared to control. Histological studies showed signifi cant increase of spermatogonia, Leydig and Sertoli cell numbers and epithelial thickness in AT group compared to other groups. All the treatment groups had higher number of Leydig, spermatogonia and spermatid cells. CONCLUSION: TT and AP improved sexual parameters; however, their simultaneous administration had higher improving effects on studied parameters.


Asunto(s)
Chrysanthemum cinerariifolium/química , Infertilidad Masculina/tratamiento farmacológico , Extractos Vegetales/uso terapéutico , Tribulus/química , Animales , Peso Corporal , Fertilidad/efectos de los fármacos , Hormona Folículo Estimulante/sangre , Humanos , Hormona Luteinizante/sangre , Masculino , Tamaño de los Órganos , Extractos Vegetales/farmacología , Ratas Wistar , Valores de Referencia , Reproducibilidad de los Resultados , Recuento de Espermatozoides , Motilidad Espermática/efectos de los fármacos , Espermatozoides/efectos de los fármacos , Testículo/efectos de los fármacos , Testosterona/sangre , Resultado del Tratamiento
20.
Int Arch Allergy Immunol ; 180(4): 284-290, 2019.
Artículo en Inglés | MEDLINE | ID: mdl-31665735

RESUMEN

BACKGROUND: Numerous products are available for subcutaneous (SCIT) and sublingual allergen-specific immunotherapy, but there are no information about the direct comparability regarding efficacy, safety, and tolerability of the different extracts. AIMS: The aim of this open-labelled, prospective, controlled observational trial was to test the feasibility of a comparison of different products for SCIT in children. METHODS: Pediatrician practices recruited patients with a confirmed diagnosis of a seasonal allergic rhinoconjunctivitis (AR) with or without asthma and an allergic sensitization against grass pollen allergen. Every patient was offered SCIT with one out of six allergen extracts: ALK SQ Depot, ALK Avanz, Allergovit, Depigoid, Purethal, Pollinex Quattro. Scores for symptoms and medications were calculated and the difference between treatment years and baseline were recorded. RESULTS: In total, 284 were recruited and 255 children (89.8%; mean age 10.4, SD 3.54 years; 65% males) participated in this trial. Overall, 49,649 patient days were recorded in the electronic database (mean 183.2 days/patient). There was no significant difference in the AR and asthma symptom score or the medication score between the six different SCIT preparations. Similarly, no differences were observed in terms of safety and tolerability. CONCLUSION: The comparison of different SCIT products using an online tool is feasible. Based on our preliminary data, all extracts indicated efficacy; however, larger groups would be necessary to demonstrate superiority or non-inferiority of one specific SCIT product.


Asunto(s)
Alérgenos/uso terapéutico , Antígenos de Plantas/uso terapéutico , Asma/terapia , Conjuntivitis Alérgica/terapia , Desensibilización Inmunológica/métodos , Extractos Vegetales/uso terapéutico , Rinitis Alérgica Estacional/terapia , Alérgenos/administración & dosificación , Antígenos de Plantas/administración & dosificación , Niño , Femenino , Humanos , Masculino , Extractos Vegetales/administración & dosificación , Estudios Prospectivos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA